Real world experience with pembrolizumab and nivolumab for treatment of non-small cell lung cancer (NSCLC) in an Irish Regional Cancer Center

被引：3
|
作者：
Dennehy, Colum
Mullally, Will
Goggin, Caitriona
Gleeson, Jack Patrick
Greene, John Patrick
Power, Derek Gerard
O'Reilly, Seamus
Collins, Dearbhaile Catherine
O'Mahony, Deirdre
Bambury, Richard Martin
机构：
[1] Cork Univ Hosp, Cork, Ireland
[2] MMUH, Dublin, Ireland
[3] Adelaide & Meath Hosp, Dublin, Ireland
[4] Mercy Univ Hosp, Cork, Ireland
[5] Inst Canc Res, Sutton, Surrey, England
[6] Royal Marsden Hosp, Sutton, Surrey, England
[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[8] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21196
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21196
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-World Experience With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer at Frankfurt University Hospital
    Shaid, S.
    Stratmann, J.
    Wolf, A.
    Niklas, N.
    Calleja, A.
    Munro, R.
    Waldenberger, D.
    Carroll, R.
    Daumont, M.
    Penrod, J.
    Lacoin, L.
    Rohde, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1003 - S1004
  • [32] Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich
    Sanoyan, D. Akhoundova
    Siebenhuner, A.
    Delaloye, R.
    Bankel, L.
    Paulino, T. D. L.
    Curioni, A.
    ANNALS OF ONCOLOGY, 2017, 28 : 7 - 7
  • [33] Experience of nivolumab and pembrolizumab in metastatic non-small cell lung cancer in routine clinical practice (mNSCLC.)
    Ksienski, Doran
    Brooks, Edward Geoffrey
    Fenton, Dave
    Fiorino, Leathia
    Geller, Georgia Samantha
    Poonja, Zia
    Glick, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [34] Profiling of immune related adverse events from nivolumab or pembrolizumab monotherapy in advanced non-small cell lung cancer in real world
    Aso, M.
    Sugawara, S.
    Toi, Y.
    Sugisaka, J.
    Ono, H.
    Tsurumi, K.
    Suzuki, K.
    Shimizu, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [36] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [37] Systemic therapy in the management of non small cell lung cancer (NSCLC): The real world experience
    Lewis, A.
    Hough, N.
    Woolf, D. K.
    Trehy, R.
    Kolotia, B.
    Reeves, A.
    Szlosarek, P. W.
    Wells, P.
    Steele, J.
    LUNG CANCER, 2013, 79 : S17 - S17
  • [38] Pembrolizumab-the "KEY" to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
    Yellala, Amulya
    Ganti, Apar Kishor
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 824 - 827
  • [39] Hyponatraemia as an unrecognised risk factor in non-small cell lung cancer (NSCLC) treatment with nivolumab.
    Grohe, Christian
    Gwynn, Simon
    Evans, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [40] REAL-WORLD UTILIZATION OF BRIGATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Lin, H. M.
    Pan, X.
    Hou, P.
    Huang, H.
    Baumann, P.
    Jahanzeb, M.
    VALUE IN HEALTH, 2019, 22 : S115 - S115
12345